Imaging in the cardiovascular and metabolic disease area

Drug Discovery Today

Volumn 18, Issue 3-4, 2013, Pages 185-192

  Comley, Robert A ^a   Kallend, David ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DALCETRAPIB; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; LOSMAPIMOD; RILAPLADIB; SULFONYLUREA RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VESICULAR MONOAMINE TRANSPORTER 2;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGING; INSULIN RESISTANCE; INSULINOMA; IONIZING RADIATION; MEDICAL DECISION MAKING; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND; WAIST CIRCUMFERENCE;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; DRUG DISCOVERY; HUMANS; METABOLIC DISEASES;

EID: 84873076819     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.09.008     Document Type: Review

References (100)

1. R.J. Hargreaves The role of molecular imaging in drug discovery and development Clin. Pharmacol. Ther. 83 2008 349 353
2. J.K. Willmann Molecular imaging in drug development Nat. Rev. Drug Discov. 7 2008 591 607
3. T.J. McCarthy The role of imaging in drug development Q. J. Nucl. Med. Mol. Imaging 53 2009 382 386
4. P.M. Matthews Non-invasive imaging in experimental medicine for drug development Curr. Opin. Pharmacol. 11 2011 501 507
5. R.L. Ehman Blueprint for imaging in biomedical research Radiology 244 2007 12 27
6. E.S.O. Radiology Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR) Insights Imaging 2 2011 621 630
7. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125 1996 605 613
8. R. Katz Biomarkers and surrogate markers: an FDA perspective NeuroRx 1 2004 189 195
9. D.A. Fryburg, and M.T. Vassileva Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response Sci. Transl. Med. 3 2011 72 76
10. O. Hurko, and G.K. Jones Valuation of biomarkers Nat. Rev. Drug Discov. 10 2011 253 254
11. E.L. Thomas Pragmatic study of orlistat 60 mg on abdominal obesity Eur. J. Clin. Nutr. 65 2011 1256 1262
12. J.M. Haus Intramyocellular lipid content and insulin sensitivity are increased following a short-term low-glycemic index diet and exercise intervention Am. J. Physiol. Endocrinol. Metab. 301 2011 E511 E516
13. E.L. Thomas Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study Gut 54 2005 122 127
14. F.H. Cassidy Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis Radiographics 29 2009 231 260
15. P. Iozzo Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals Gastroenterology 139 2010 846 856 E841-E846
16. A. De Silva The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans Cell Metab. 14 2011 700 706
17. D. Vancraeynest Imaging the vulnerable plaque J. Am. Coll. Cardiol. 57 2011 1961 1979
18. D.R. Owen Imaging of atherosclerosis Annu. Rev. Med. 62 2011 25 40
19. E.C. Rizos The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review Curr. Vasc. Pharmacol. 8 2010 638 644
20. 13N-ammonia positron emission tomography J. Nucl. Cardiol. 17 2010 1015 1022
21. K. Yoshinaga Assessment of coronary endothelial function using PET J. Nucl. Cardiol. 18 2011 486 500
22. S.A. Kajander Clinical value of absolute quantification of myocardial perfusion with (15)O-water in coronary artery disease Circ. Cardiovasc. Imaging 4 2011 678 684
23. W. Chan Principles, current status and clinical implications of ischaemic heart disease assessment by cardiac magnetic resonance imaging Intern. Med. J. 42 2012 7 17
24. S.J. Shah Phase II trials in heart failure: the role of cardiovascular imaging Am. Heart J. 162 2011 3 15 E13
25. J.R. Lewis, and S.R. Mohanty Nonalcoholic fatty liver disease: a review and update Dig. Dis. Sci. 55 2010 560 578
26. T. McLaughlin Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity J. Clin. Endocrinol. Metab. 96 2011 E1756 E1760
27. J.P. Montani Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases Int. J. Obes. Relat. Metab. Disord. 28 Suppl. 4 2004 S58 S65
28. T.D. Wang Association of epicardial adipose tissue with coronary atherosclerosis is region-specific and independent of conventional risk factors and intra-abdominal adiposity Atherosclerosis 213 2010 279 287
29. E.L. Thomas The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat Obesity (Silver Spring) 20 2012 76 87
30. K.J. Ellis Human body composition: in vivo methods Physiol. Rev. 80 2000 649 680
31. S. Mattsson, and B.J. Thomas Development of methods for body composition studies Phys. Med. Biol. 51 2006 R203 R228
32. H.J. Silver Imaging body composition in obesity and weight loss: challenges and opportunities Diabetes Metab. Syndr. Obes. 3 2010 337 347
33. H.H. Hu Assessment of abdominal adipose tissue and organ fat content by magnetic resonance imaging Obes. Rev. 12 2011 E504 E515
34. S.B. Reeder Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy J. Magn. Reson. Imaging 34 2011 729 749
35. J. Levy Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study Diabet. Med. 15 1998 290 296
36. T.A. Buchanan Pancreatic beta-cell loss and preservation in type 2 diabetes Clin. Ther. 25 Suppl. B 2003 B32 B46
37. S.E. Kahn The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes Diabetologia 46 2003 3 19
38. E. Ferrannini, and A. Mari Beta cell function and its relation to insulin action in humans: a critical appraisal Diabetologia 47 2004 943 956
39. P. Marchetti An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment Regul. Pept. 146 2008 4 11
40. P. Westermark, and E. Wilander The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus Diabetologia 15 1978 417 421
41. K. Saito Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas Tohoku J. Exp. Med. 124 1978 177 186
42. H. Sakuraba Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients Diabetologia 45 2002 85 96
43. K.H. Yoon Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea J. Clin. Endocrinol. Metab. 88 2003 2300 2308
44. A.E. Butler Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110
45. S. Del Guerra Functional and molecular defects of pancreatic islets in human type 2 diabetes Diabetes 54 2005 727 735
46. P. Marchetti Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin J. Clin. Endocrinol. Metab. 89 2004 5535 5541
47. B. Gallwitz The fate of beta-cells in type 2 diabetes and the possible role of pharmacological interventions Rev. Diab. Stud. 3 2006 208 216
48. I.W. Campbell, and S. Mariz Beta-cell preservation with thiazolidinediones Diabetes Res. Clin. Pract. 76 2007 163 176
49. D.R. Matthews Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
50. M. Brom Development of radiotracers for the determination of the beta-cell mass in vivo Curr. Pharm. Des. 16 2010 1561 1567
51. Z. Wu, and F. Kandeel Radionuclide probes for molecular imaging of pancreatic beta-cells Adv. Drug Deliv. Rev. 62 2010 1125 1138
52. G.W. Cline Islet-selectivity of G-protein coupled receptor ligands evaluated for PET imaging of pancreatic beta-cell mass Biochem. Biophys. Res. Commun. 412 2011 413 418
53. E. Mukai GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging Biochem. Biophys. Res. Commun. 389 2009 523 526
54. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma Eur. J. Nucl. Med. Mol. Imaging 39 2012 463 473
55. Z. Wu In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40- Exendin-4 by targeting GLP-1 receptor Bioconjug. Chem. 22 2011 1587 1594
56. Y. Zhang, and W. Chen Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic beta-cell imaging agent Nucl. Med. Commun. 33 2012 223 227
57. S. Schneider In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans Exp. Clin. Endocrinol. Diabetes 113 2005 388 395
58. S. Schneider Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents Regul. Pept. 139 2007 122 127
59. F. Souza Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model J. Clin. Invest. 116 2006 1506 1513
60. 11C]DTBZ Nucl. Med. Biol. 33 2006 855 864
61. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls J. Nucl. Med. 50 2009 382 389
62. R. Veluthakal, and P. Harris In vivo beta-cell imaging with VMAT 2 ligands-current state-of-the-art and future perspective Curr. Pharm. Des. 16 2010 1568 1581
63. T.C. Kwee Beta-cell imaging: opportunities and limitations J. Nucl. Med. 52 2011 493 author reply 493-495
64. M. Ichise, and P.E. Harris Beta-cell imaging: opportunities and limitations J. Nucl. Med. 52 2011 493 495
65. 18F-fluoropropyl- dihydrotetrabenazine and PET J. Nucl. Med. 53 2012 908 916
66. 18F-FP-DTBZ J. Nucl. Med. 2012 Meeting Abstracts 53 (1-MeetingAbstracts), 98
67. V. Fagerholm Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas J. Nucl. Med. 51 2010 1439 1446
68. 11C-dihydrotetrabenazine beta-cell imaging J. Nucl. Med. 51 2010 1335 1336
69. J. Virostko Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands Proc. Natl. Acad. Sci. U. S. A. 108 2011 20719 20724
70. N. Ballian, and F.C. Brunicardi Islet vasculature as a regulator of endocrine pancreas function World J. Surg. 31 2007 705 714
71. C.W. Yu Correlation between pancreatic microcirculation and type 2 diabetes in patients with coronary artery disease: dynamic contrast-enhanced MR imaging Radiology 252 2009 704 711
72. J.H. Naish Multiple-bolus dynamic contrast-enhanced MRI in the pancreas during a glucose challenge J. Magn. Reson. Imaging 32 2010 622 628
73. J.A.K. Blokland Positron emission tomography: a technical introduction for clinicians Eur. J. Radiol. 44 2002 70 75
74. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J. Nucl. Med. 50 2009 1820 1827
75. J.H. Rudd Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J. Am. Coll. Cardiol. 55 2010 2527 2535
76. 18fluorine-labeled 2-deoxy-d-glucose positron emission tomography J. Am. Coll. Cardiol. 58 2011 603 614
77. A. Tawakol Classical but not innate activation augments 2-deoxy-d-glucose uptake in macrophages: implications for atherosclerosis imaging J. Nucl. Med. 2012 Meeting Abstracts 53 (1-MeetingAbstracts), 464
78. N. Tahara Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography J. Am. Coll. Cardiol. 48 2006 1825 1831
79. H. Ishii Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention Clin. Ther. 32 2010 2337 2347
80. Z.A. Fayad Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 2011 1547 1559
81. GlaxoSmithKline Result Summary for PM1111138, Vol. 2012 2012 http://www.gsk-clinicalstudyregister.com/
82. GlaxoSmithKline Result Summary for LP2105521 2012 http://www.gsk- clinicalstudyregister.com/
83. J.C. Wu, and P.K. Nguyen Imaging atherosclerosis with F18-fluorodeoxyglucose positron emission tomography: what are we actually seeing? J. Am. Coll. Cardiol. 58 2011 615 617
84. 18F-FDG uptake to macrophages in vitro J. Nucl. Med. 53 2012 55 58
85. R. Corti, and V. Fuster Imaging of atherosclerosis: magnetic resonance imaging Eur. Heart J. 32 2011 1709 1719
86. X.Q. Zhao MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course JACC Cardiovasc. Imaging 4 2011 977 986
87. V. Mani Carotid black blood MRI burden of atherosclerotic disease assessment correlates with ultrasound intima-media thickness J. Cardiovasc. Magn. Reson. 8 2006 529 534
88. H.R. Underhill Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial Am. Heart J. 155 2008 584 E581-E588
89. P.M. Ridker Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N. Engl. J. Med. 359 2008 2195 2207
90. J.M. Lee Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J. Am. Coll. Cardiol. 54 2009 1787 1794
91. W.E. Boden Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 2011 2255 2267
92. S. Hermann Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability? J. Nucl. Cardiol. 19 2012 609 617
93. T. Quillard Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo Thromb. Haemost. 105 2011 828 836
94. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis JACC Cardiovasc. Imaging 2 2009 1213 1222
95. F. Rouzet Radiolabeled fucoidan as a p-selectin targeting agent for in vivo imaging of platelet-rich thrombus and endothelial activation J. Nucl. Med. 52 2011 1433 1440
96. H.H. Boersma P-selectin imaging in cardiovascular disease: what you see is what you get? J. Nucl. Med. 52 2011 1337 1338
97. 11C-acetate PET/CT for imaging of fatty acid synthesis in the atherosclerotic vessel wall J. Nucl. Med. 52 2011 1848 1854
98. 18F-sodium fluoride uptake: a novel marker of plaque biology J. Am. Coll. Cardiol. 59 2012 1539 1548
99. H. Li Synthesis of beta-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals Chem. Commun. (Camb.) 48 2012 3385 3387
100. R.G. Schwartz Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial J. Am. Coll. Cardiol. 42 2003 600 610